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ABSTRACT
Thyroid hormone receptors (TRs) are members of the
nuclear hormone receptor superfamily, which act as
transcription factors upon binding to specific DNA
sequences called thyroid hormone (T3) response
elements (TREs). Such elements are found in the
upstream regulatory region of promoters as well as in
intragenic sequences of T3-responsive genes. In this
report, we demonstrate that SV40 late (SVL) promoter
activity is strongly down-regulated by TR in the absence
of ligand. Addition of T3 releases this repression, but
does not further induce SVL promoter activity. Electro-
phoretic mobility shift analyses reveal a TR binding
element that overlaps with the SV40 major late tran-
scription initiation site. This element closely fits the
consensus TRE, formed of two hexanucleotides
organized in a tandem repeat separated by 4 nt, and is
able to confer T3 responsiveness on a heterologous
promoter. We further show that, although the presence
of TR leads to quantitatively modified expression of an
SVL-driven reporter gene, neither displacement of the
site of transcription initiation nor modification of the
splicing pattern of the primary transcripts occur.
INTRODUCTION
Thyroid hormone receptors (TRs) belong to the superfamily of
nuclear receptors, together with receptors such as those for steroid
hormones, vitamin D and retinoic acid (reviewed in 1). They bind
to specific DNA sequences, called thyroid hormone response
elements (TREs), and act as transcription factors that modulate
the promoter activity of TRE-containing genes. The TREs are
composed of two half-sites derived from the consensus hexamer
AGGTCA, arranged either as a palindrome, a direct repeat or as
an inverted palindromic array, with a spacing between the two
hexamers of 0, 4 and 6 nt respectively (reviewed in 2). TR
preferentially binds as a heterodimer with RXR, another member
of the nuclear receptor superfamily, but it can also bind as a
homodimer or as a monomer. In in vitro binding assays as well as
in vivo within the chromosomal chromatin context (3) TR binds
to its element in the absence of thyroid hormone (T3). Binding of
unliganded TR results in transcriptional repression, as measured
in functional assays, while the addition of T3 not only relieves this
repression but allows a further activation of transcription above
the derepressed basal level. However, with some specific
response elements and promoter contexts T3 may lead to negative
regulation of target gene expression (reviewed in 4).
For most DNA viruses, promoter activation depends on use of
the transcriptional apparatus of the host cell. Analyses of
transcriptional regulatory mechanisms in mammalian cells have
largely benefitted from the use of these viruses as models
(reviewed in 5). Indeed, the first described hormone response
elements were glucocorticoid response elements found in the
long terminal repeat (LTR) of mouse mammary tumor virus
(MMTV) (reviewed in 6). Simian virus 40 (SV40), with its small
circular double-stranded DNA genome, provided one of the first
tools for characterizing enhancer elements (reviewed in 7,8). The
SV40 late (SVL) promoter is a well-characterized TATA-less
promoter and, as for most members of this class of promoters,
transcription can initiate at multiple sites. However, the major
start site maps at nt 325 with respect to the Buchman numbering
of the SV40 genome (9) and accounts for 80–90% of total late
RNA synthesis (10 and references therein). Upstream regulatory
cis-elements modulating the level of late expression include the
SV40 origin of replication, the three 21 bp repeats and the 72 bp
direct repeat (11,12 and references therein). The core promoter of
SVL consists of three elements which are sufficient for basal
promoter activity and specify the start site of major late RNA
synthesis. One of these elements is centred at nt 294 and functions
as a binding site for TFIID (13), while the two other sites are
centred at nt 325, i.e. the transcription initiation site itself, and at
nt 352 (14). More recently, Wiley et al. (15) showed that some
cellular transcriptional repressors, collectively called initiator
binding proteins, bind to sequences located at and close to the
transcription initiation site and might be involved in the SV40
early to late switch.
The strength of many viral promoters, together with the
characteristics of specific viral sequences involved in messenger
RNA maturation, also led to their development as tools for efficient
expression of exogenous proteins in mammalian cells. Such
expression vectors contain a viral promoter, which drives mRNA
synthesis from inserted foreign cDNAs, as well as a sequence
containing splicing acceptor/donor sites and a polyadenylation
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Figure 1. (A) Schematic representation of the vector pSVL with the site of insertion of the CAT coding sequence. The sequence coordinates of the SV40 genome
fragments, boxed in grey, are given. PL, polylinker sequence. (B) Regulation of pSVL-CAT expression by TRα and T3. NIH 3T3 cells were transfected by
electroporation with 5 µg pSVL-CAT, 3.2 µg pSG5-TRα (TRα+) or 3.2 µg empty vector pSG5 (TRα–) and 5 µg PUC19 as carrier DNA; 0.25 µg pCMVβ expression
vector were added as an internal control for transfection efficiency. Cells were cultured for 72 h in the presence (+) or absence (–) of T3. (Left) CAT activity present
in the corresponding cellular extracts normalized to β-galactosidase activity and expressed as a percentage of CAT reporter activity measured in the absence of TR
and T3 at 10–7 M. Values are the mean ± SD of three independent experiments, each performed in triplicate. (Right) T3 dose–response curve of pSVL-CAT activity
in the presence of TRα. 100% corresponds to maximal T3 activation, obtained at 10–7 M.
signal. While attempting to take advantage of pSVL, a SVL-derived
vector, to drive expression of TRs, preliminary experiments
suggested to us that TR itself was affecting the efficiency of the
pSVL vector. In this work we demonstrate that a functional and
potent TRE overlaps with the SV40 major late transcription
initiation site and we further characterize the regulatory role of
TR in this unusual context.
MATERIALS AND METHODS
Plasmid constructions
pSVL-CAT was obtained by inserting the chloramphenicol
acetyltransferase (CAT) coding sequence into the BamHI site of
pSVL (Pharmacia LKB Biotechnology). For the pTRE-
SVL-TKCAT construct, a synthetic double-stranded oligonucleo-
tide encompassing the SVL sequence from nt 308 to 339 and
flanked on its 5′- and 3′-side by a HindIII and BamHI restriction
site respectively was inserted into the pBLCAT2 reporter plasmid
(16) upstream of the –105 base pair of the TK promoter. In
pTRESVL-CAT, the same oligonucleotide was introduced into the
promoterless vector pBLCAT3 (16). For the vector pSVL-neo,
the SVL sequence from nt 39 to 417 was PCR amplified using
corresponding 5′ and 3′ primers with an extended sequence
encompassing a NdeI and HindIII restriction site respectively.
The MMTV LTR was removed from pMAM-neo (Clontech) by
NdeI/HindIII digestion and replaced by the amplified fragment.
For in vitro transcription/translation and for transfections, the rat
TRα cDNA was inserted into a modified pSG5 (pSG5PL, a gift
from Dr H.Richard-Foy).
Cell culture and transfections
NIH 3T3 cell maintenance and transfection were performed as
described previously (17). pCMVβ (Clontech), which expresses
β-galactosidase, was used as an internal control of transfection
efficiency. Following transfection, cells were harvested after a 72 h
incubation in hormone-free medium (18) with or without 10–7 M
T3 (Sigma). CAT and β-galactosidase activities were assayed as
described (17,19). Total RNA was prepared from transfected
cells using the TRIZOL reagent (Gibco), according to the
manufacturer’s instructions. To eliminate possible contamination
with co-purified small DNA molecules such as plasmids, RNA
preparations were further digested with a RNase-free DNase
(RQ1 DNase) for 30 min at 37C.
Electrophoretic mobility shift assay
The probes, DNA restriction fragments or double-stranded
oligonucleotides were 32P-end-labelled by a Klenow fragment
filling-in reaction. In vitro transcription was performed on linearized
pSG5-TRα and followed by in vitro translation according to the
manufacturer’s protocols (Promega). Binding reactions were
carried out by incubating 3 µl unprogrammed or programmed
reticulocyte lysate and 0.5 µl nuclear extract from Sf9 cells
infected with a recombinant baculovirus overexpressing mouse
RXRβ (prepared as described in 20,21), in the presence of 22 mM
HEPES, 1.25 mM dithiothreitol, 2.5 mM MgCl2, 40 mM KCl,
12% glycerol and 250 µg/ml poly(dA·dT) in a 20 µl reaction to
which 20 000 c.p.m. labeled probe were added. For competition
experiments, the indicated molar excess of unlabelled double-
stranded oligonucleotide was added to the mixture. When used,
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Figure 2. The SVL promoter fragment from the KpnI (294) to the HpaI (498) site contains a binding site for TRα. (A) Schematic diagram of the probes tested in binding
assays with TRα and RXR. Probes A and D (dotted lines) did not allow formation of TR–RXR complexes, while probes B and C (plain lines) were positive. Boxes
(21s) and (72s) correspond to enhancer elements characterized for the SV40 early and late promoters. (B) Binding reactions with probe C. In vitro translated TRα (TR)
or unprogrammed lysate (Co) in the presence or absence of nuclear extracts from Sf9 cells infected with a recombinant baculovirus expressing RXRβ (+ or – as
indicated in the figure) were mixed with 20 000 c.p.m. radiolabelled probe C and the reaction performed as described in Materials and Methods. In lane 6, T3 has been
added at a final concentration of 10–7 M. Competition for binding to the probe was achieved using a 100-fold molar excess of an unlabelled double-stranded
oligonucleotide either specific, encompassing TREME (S; lane 7), or non-specific, bearing an unrelated sequence (NS; lane 8).
T3 was at a final concentration of 10–7 M. Incubation, electrophore-
sis and exposure were performed as previously described (17).
S1 nuclease
Probe preparation. The vector pSVL-neo was digested with SphI
and used as template in asymmetric PCR. A 32P-end-labelled
oligonucleotide complementary to 25 bases within the neomycin
resistance gene cDNA was used as unique primer (see Fig. 7A).
After 30 cycles at an annealing temperature of 55C, the PCR
reaction was subjected to electrophoresis on a 6% polyacrylamide–
8 M urea gel. The band corresponding to the specific labelled
single-stranded DNA was identified after a 2 min exposure of the
wet gel, eluted in 0.5 M ammonium acetate, 1 mM EDTA,
precipitated and resuspended in TE.
S1 nuclease assay. Aliquots of 20 µg total RNA from NIH 3T3
cells, transfected and treated as indicated, were hybridized
overnight at 30C with 50 000 c.p.m. probe in the presence of
80% formamide, 0.4 M NaCl, 40 mM PIPES, pH 6.4, 1 mM
EDTA, pH 8.0. After a 10-fold dilution of the hybridization
mixture with 0.28 M NaCl, 4.5 mM ZnSO4, 50 mM sodium
acetate, pH 4.5, 300 U S1 nuclease (Pharmacia) were added for
a 1 h incubation at 30C in the presence of 2 µg single-stranded
calf thymus DNA. The reaction was stopped by adding 80 µl stop
solution (4 M ammonium acetate, 20 mM EDTA, pH 8.0, 40 µg/ml
tRNA), precipitated and resuspended in 3 µl TE and 4 µl RNA
loading buffer (80% formamide, 1 mM EDTA, pH 8.0, 0.1%
bromophenol blue, 0.1% xylene cyanol). After denaturation for
5 min at 95C, the samples were electrophoresed on 6%
polyacrylamide–8 M urea gels in 1× TBE. Autoradiography of
the gel was performed with a 10 day exposure.
RT–PCR
Aliquots of 20 µg total RNA from NIH 3T3 cells, transfected and
treated as indicated, were co-precipitated with 3 pmol CAT
primer or 3 pmol act2 primer, resuspended in 80 mM Tris–HCl,
pH 8.3, 80 mM KCl and hybridized overnight at 52C. The
reverse transcriptase buffer (33 mM Tris–HCl, pH 8.3, 33 mM
KCl, 10 mM MgCl2, 16 mM DTT, 1 mM 4 mix dNTP, 10 U
RNasin) and 16 U AMV reverse transcriptase were added for an
incubation of 1 h at 42C. The reaction was stopped with
phenol/chloroform extraction of the cDNA, which was then
ethanol precipitated and resuspended in water. The cDNA was
then used as template for the PCR amplification using four
different pairs of primers: p1/CAT, p2/CAT, p1/p3 and act1/act2.
Aliquots of 2.5 µg cDNA were mixed with 2 µM each primer,
0.2 mM each dNTP, 2 mM MgCl2, 20 mM Tris–HCl, pH 8.4,
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Figure 3. (A) Sequence surrounding the major transcription initiation site of the
SVL promoter. The sequences of the oligonucleotides used in competition
assays are underlined; plain line, efficient competition for TR–RXR binding to
probe C (described in Fig. 2); dotted lines, no competition. (B) Sequence and
coordinates of the TR–RXR binding site contained in the SVL promoter
(TRESVL) aligned with those of the Xenopus TRβΑ gene (TRExTRβ) and those
of the malic enzyme gene (TREME). The double arrows indicate the two
hexamers corresponding to consensus half-sites, organized for each of these
TREs as a direct repeat with a four base pair spacing.
50 mM KCl and 1 U Taq polymerase. After 39 cycles, the PCR
reaction products were loaded on a 1.2% agarose gel in 1× TBE.
The respective position of the primers p1 (AACGCCTTTTTGT-
GTTTGTT), p2 (TATCATTTGGGCACACCTAT), p3 (CTA-
CAGCCATTCCTGGTTGT) and CAT (GCAACTGACTGAAAT-
GCC TC) are shown in Figure 6A. The primers act1 (ATATCGC-
TGCGCTGGTCGTCGACAA) and act2 (AGCACAGCCTGG-
ATGGCTACGTACA) correspond to the mouse β-actin cDNA
from nt 91 to 115 and from nt 499 to 475 respectively.
RESULTS
Activity of the reporter gene pSVL-CAT is repressed by
unliganded TRα
The pSVL vector contains a SV40 genome fragment from nt 4739
to 1495 comprising the origin of replication, the SVL promoter,
the leader sequences and the VP1 intron, as well as the SV40
polyadenylation signal from nt 2533 to 2770 (Fig. 1A). Because
of the removal of the first ATG of VP1, this vector allows
expression of protein starting with the first ATG of the cDNA
inserted in the polylinker (PL) sequence. To monitor activity of
the SVL promoter and to analyse its regulation, we inserted the
CAT coding sequence into the BamHI site and used this reporter
gene in transfection assays performed in NIH 3T3 cells, which do
not express detectable levels of endogenous TR. Expression of
the α subtype of TR (TRα) reduces basal activity of the
pSVL-CAT construct by 85%. Addition of T3 to the cell culture
medium relieves this repression in a dose-dependent manner,
restoring CAT activity close to the basal level at 10–7 M (Fig. 1B).
The same results were obtained when using TRβ1, the other TR
subtype, though derepression in the presence of T3 was less
efficient than that observed with TRα. In contrast, overexpression
of c-erbAα2, which is an alternative product of the TRα gene and
which does not bind T3 (22), does not modify SVL promoter
Figure 4. TRESVL is a high affinity binding site for the TRα–RXR heterodimer.
Competition analyses were performed using EMSA as described in Materials
and Methods. (A) EMSA with the oligonucleotide containing the TRESVL
sequence as probe. (B) EMSA with the oligonucleotide containing the TREME
sequence as probe. Competitors correspond to 33 bp double-stranded
oligonucleotides encompassing either TRESVL (lanes 2–7) or TREME (lanes
8–13) or an unrelated sequence (NS, lane 14) at the indicated fold molar excess.
activity in the absence or presence of T3 (data not shown). Thus,
these results provide evidence for regulation of SVL promoter
activity by TR and T3.
The heterodimer TRα–RXR binds to an element within the
SVL promoter
We thus searched for the putative TRE mediating TR action in
pSVL-CAT by performing electrophoretic mobility shift analyses
(EMSA) with TR and RXR. We first tested two probes, A and B,
covering a total of 651 bp of the promoter sequence from nt 5171
to 587 (Fig. 2A). Since only probe B exhibited strong binding of
the TR–RXR complex (data not shown), probes C and D derived
from B were used and the TR–RXR binding region was mapped
to the KpnI–HpaI DNA fragment C (nt 294–499). As seen in
Figure 2B, neither TRα alone nor RXRβ alone is able to bind to
this probe, while a strong complex, migrating as a single band,
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Figure 5. The SVL sequence which binds TRα is a functional TRE. Five
micrograms of various CAT reporter genes as indicated were transfected into
NIH 3T3 cells together with 12 µg PUC19 (carrier DNA) and 0.25 µg pCMVβ
expression vector (internal control) and with 3.2 µg expression vector
pSG5-TRα (TR+) or the empty vector PSG5PL (TR–). The fold induction
corresponds to the ratio of the normalized CAT activity present in T3-treated
cells over that present in non-treated cells and is the mean ± SD of three
independent experiments, each performed in duplicate. No transcriptional
activity was detected (No Detect.) with the pTRESVL-CAT construct.
appears when both TRα and RXR are present in the binding
reaction. As expected for a TRα–RXR heterodimer, addition of
T3 does not alter the amount of this complex but provokes a very
small but reproducible down-shift (Fig. 2B, compare lanes 5 and
6). The retarded band is specifically competed out by a 100-fold
excess of an oligonucleotide corresponding to the TRE of the
malic enzyme gene (TREME) (17) but not by the same excess of
an unrelated competitor (Fig. 2B, lanes 7 and 8).
Sequence analysis of DNA fragment C reveals three sites
bearing some resemblance to a TRE, in the region shown in
Figure 3A. The first putative binding site corresponds to the DNA
sequence from nt 289 to 323, previously shown to be an element
of the SVL core promoter. The second site, from nt 310 to 339,
contains the major late initiation site, while the third site, from nt
366 to 394, has recently been described as containing a binding
site for human testicular receptor 2 (TR2) and testicular receptor 4
(TR4), which are orphan receptors that also belong to the nuclear
receptor superfamily (23). The corresponding double-stranded
oligonucleotides were synthesized and used as competitors in an
EMSA. Only oligonucleotide 308/339 is able to efficiently
compete out formation of the TR–RXR retarded complex bound
to the KpnI–HpaI DNA fragment, while oligonucleotides
288/323 and 366/397 give only poor or no competition respectively
(data not shown). In Figure 3B, the newly identified TR–RXR
binding site is compared with the well-characterized TREME. A
good level of similarity is found when considering the sequence
of the two hexanucleotides forming each half-site (10 nt out of
12). However, the resemblance of the SVL element with a TRE
recently characterized in the promoter region of the Xenopus
TRβA gene (3) is even more striking, since the identity also
encompasses the four spacing base pairs.
To assess the relative strength in terms of TR–RXR binding of
this newly discovered TRE, hereafter referred to as TRESVL, we
used it in reciprocal competition with TREME. As seen in Figure 4A,
binding of the TRα–RXR complex to the SVL probe is more
efficiently competed out by TRESVL than by TREME. In
agreement with this result, TRα–RXR complexes bound to the
ME probe are also more efficiently displaced by TRESVL than by
TREME (Fig. 4B), confirming that TRESVL is a potent TR binding
site.
The TRα–RXR binding site of the SVL promoter acts as a
positive TRE in a heterologous promoter
To test if TRESVL has the capability of mediating an in vivo T3
response, we inserted it upstream of the thymidine kinase (TK)
promoter in pBLCAT2 and tested this reporter gene activity by
transfection into NIH 3T3 cells. For comparison we used the same
reporter construct containing the previously described TREME
(pTK1AM; 17). Co-transfection of the TRα-expressing vector
leads to repression of the basal activity of TRE-containing
promoters while it does not affect that of pBLCAT2 (data not
shown). Under these conditions, addition of T3 does not simply
relieve this repression but also provokes a high level of induction
above the basal level, resulting in a final 150-fold induction of
pTRESVL-TKCAT activity and 550-fold for pTK1AM activity
(Fig. 5). Interestingly, in the absence of overexpressed TRα, the
basal activity of pTRESVL-TKCAT is significantly higher than
that of the parent vector pBLCAT2. Moreover, T3 does not
significantly affect expression of the control vector or of pTK1AM
while it provokes a significant 7-fold induction of pTRE-
SVL-TKCAT activity, for reasons which are not clear at this time.
Since TRESVL corresponds to the main transcription initiation
site of the SVL promoter, we inserted it into the promoterless
vector pBLCAT3 and tested it in transfections. However, neither
basal nor induced activity of this new pTRESVL-CAT construct
could be detected in the presence or absence of TRα and/or T3
(Fig. 5).
In summary, these data demonstrate that TRESVL can confer T3
responsiveness to a heterologous promoter and has the property
of a regular positive TRE.
TR does not affect splicing of RNAs expressed from the
pSVL vector
One particularity of the vector pSVL used in this study is the
presence of the VP1 intron sequence, from nt 525 to 1462.
Because T3 has been shown to alter alternative splicing of the tau
gene primary transcript during development (24), we verified that
such a mechanism was not involved in regulation by T3 of gene
expression driven by the SVL promoter. For this purpose we
designed a RT–PCR-based assay to detect the presence of spliced
and unspliced CAT mRNA. After transfection into NIH 3T3 cells
of pSVL-CAT with or without the TR expression vector and in the
presence or absence of hormone, followed by RNA extraction, we
used the strategy summarized in Figure 6A to specifically amplify
the CAT mRNAs by RT–PCR. The first pair of primers, p1/CAT,
specifically amplifies a product of 320 bp, corresponding to
spliced CAT mRNA, as well as a product of 1260 bp,
corresponding to unspliced CAT mRNA, from transfected cells
but not from control cells (Fig. 6B, left, lanes 2–5). To further
assess the presence of the unspliced form, we used two different
pairs of primers designed for specific amplification of unspliced
CAT mRNA: p2/CAT and p1/p3 (Fig. 6A). The corresponding
RT–PCR assay indeed revealed single specific products of 400
and 480 bp respectively, whose presence was observed in the
presence as well as in the absence of TR and T3 (Fig. 6B, middle,
and data not shown respectively). As a control we performed a
parallel RT–PCR assay using actin-specific primers (Fig. 6B,
right). Thus, while our experimental design did not allow for
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Figure 6. Splicing of CAT mRNAs in the presence and absence of TR. (A) Localization of the primers (p1, p2, p3 and CAT) used to test the presence of spliced and
unspliced mRNA produced by pSVL-CAT transfected into NIH 3T3 cells and representation of the amplified product. The primers act1 and act2, used in a control
reaction, amplified a 410 bp fragment and are described in Materials and Methods. (B) RT–PCR assays were performed on 20 µg total RNA extracted from NIH 3T3
cells transfected with pSVL-CAT, together with pSG5-TRα or alone (TR+ or –) and cultured in the presence or absence of T3 (T3+ or –). Reactions were loaded on
a 1.2% agarose gel, stained with ethidium bromide and recorded as digital images. The free primers are marked by a star. The closed arrowheads indicate the positions
of the specific bands. Lane 1 in each panel corresponds to a reaction performed with total RNA prepared from non-transfected NIH 3T3 cells.
quantitative evaluation, we demonstrate that both spliced and
unspliced CAT mRNAs are detected, regardless of the presence
or absence of TR and T3, and thus that TR-dependent repression
of CAT activity is not due to an alteration of messenger RNA
processing.
Binding of TR at the major late transcription initiation site
does not shift transcription initiation
Because TRESVL comprises the major transcription initiation site
of the SVL promoter, we analysed the possibility of a change of
position of this site in the presence of TR. Preliminary experiments
using primer extension as well as S1 nuclease and RNase
protection assays suggested that the presence of both spliced and
unspliced messages was impeding these experiments. We thus
constructed a pSVL-neo vector in which the VP1 intron sequence
was removed together with the splicing junctions (Fig. 7A). Total
RNA was then prepared from NIH 3T3 cells transfected with the
pSVL-neo vector with or without the TR expression vector. To
determine the transcription initiation site, we performed an S1
nuclease assay using a single-stranded DNA probe encompassing
the TRE/transcription initiation site at nt 325 (Fig. 7A). The
experimental design did not allow for quantification of the
transcripts and the signal strength differences in the experiment
shown in Figure 7B were not reproducible. However, all three
independent transfections and S1 nuclease assays performed
showed that within the 400 bases covered by the probe, only one
transcription initation site is detectable, regardless of the culture
and transfection protocol (Fig. 7B). A sequencing reaction
performed with a primer corresponding to the neomycin end of
the probe allowed us to precisely position this initiation site at nt
325, which is indeed the usual major late transcription initiation
site. Thus, while binding of TR to the transcription initiation site
strikingly reduces SVL-driven expression, it does not lead to a
change of position of transcription initiation.
DISCUSSION
In this paper we have identified and functionally characterized a
TRE present at the major late transcription inititation site of the
SVL promoter. Many binding sites for transcription factors were
first described in viral promoters (reviewed in 5) and hormone
response elements (HREs) such as the one described herein are
no exception. The role of such response elements in the viral cycle
remains to be elucidated. However, one very important fact is that
viral promoters continue to be important tools to further our
understanding of the mechanisms of transcription regulation of
mammalian genes. In that respect, our discovery of a TRE at an
unusual location in the SVL promoter has two consequences.
First, it gives us a new tool to extend our understanding of the T3
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Figure 7. S1 nuclease analysis of the pSVL-neo transcripts. (A) Schematic
diagram of the SVL–neo vector which does not contain the SVL intron
sequence. The single-stranded S1 probe is drawn with its labelled end indicated
by a star. The same primer (black line) was used for generating the S1 probe and
for the sequencing reaction loaded in parallel with the S1 nuclease reactions (see
Materials and Methods). (B) S1 nuclease analyses were performed on 20 µg
RNA extracted from NIH 3T3 cells transfected with pSVL-neo, alone or
together with pSG5-TRα (TR– or +) and cultured in the presence or absence
of T3 (T3+ or –). A start site is observed at nt 325, corresponding to the major
initiation site used by the wild-type SV40 virus for its late transcription. No
other initiation sites appear upon addition of TRα and/or T3.
mechanism of action. Second, it implies that one should be
cautious when using a SVL-derived expression vector in studies
on thyroid hormone responsiveness. A similar warning has also
been propounded for the use of the luciferase reporter gene, which
bears, within the structural gene sequence, a potent T3-dependent
negative regulatory element (25).
Interestingly, two non-classical TREs have been previously
described in viral promoters. One of these is present in the
thymidine kinase gene of Herpes sarcoma virus (HSV TK). It
requires a functional interaction with the CTF/NF1 binding
sequence located 80 bp upstream of it to be active (26). This
interaction is likely to be tissue specific, since T3 regulation of the
TK promoter has been described in GH4C1 cells but is not found
in other cell lines (17,27–31 and this study). The second TRE, in
the Rous sarcoma virus LTR, mediates ligand-independent
activation by TR, activation that is inhibited by T3 (32). In
contrast to these two atypical TREs, the sequence and function of
TRESVL described herein better resembles that of mammalian
gene TREs, as will be discussed below.
The positive regulation by T3 of gene expression mediated by
TRE-bound TR can be described as a stepwise process. In the
absence of T3, TR binding to a regular positive TRE represses
basal promoter activity. Addition of T3 leads first to promoter
derepression, followed by a further stimulation well over basal
levels of target gene activity. At the molecular level, the
mechanisms involved are thought to operate as follows. Repression
by TR in the absence of hormone implies that TR heterodimerizes
with its RXR partner and binds to the TRE, as demonstrated both
in vitro and in vivo (3). Upon binding to the TRE, the TR may
directly interact with TFIIB (33) or with TBP (34) to repress RNA
polymerase II activity. Alternatively, a newly discovered mechanism
involves the interaction of TR with silencing factors such as
N-CoR and SMRT (35–37). Addition of T3 first releases the
interaction of these silencing factors with TR. Additionally, T3
allows interaction of TR with co-activators such as SRC-1 and
CBP/P300 (38,39). It is then tempting to match derepression with
T3-induced release of repressors and further induction of target gene
expression with T3-induced interaction of TR with co-activators.
With respect to the patterns of T3-mediated regulation of gene
expression, the TRESVL that we have characterized is located at
the transcription initiation site but, nonetheless, does not drive
T3-dependent inhibition of SVL promoter activity, as has been
described for some TREs found in close proximity to the
transcription initiation sites they control (reviewed in 4). The
observed pattern rather corresponds to an altered positive
regulation in which the addition of T3 would lead to relief of
repression mediated by TR, possibly by releasing interaction with
a co-repressor, while the second step of the activation process, i.e.
interaction with a co-activator, would not take place or not lead
to an efficient TR–co-activator complex. When removed from its
native context and inserted into the heterologous TK promoter,
TRESVL, which is arranged as a DR4 element, behaves strictly as
a classical positive TRE, implying that the TRESVL structure per se
allows the molecular steps described above, i.e. repression,
derepression and stimulation. Therefore, the position of the TRE
at the transcription initiation site of the SVL promoter may
account for the lack of stimulation after derepression.
Our demonstration that transcription starts at the same position
in the SVL promoter regardless of the presence or absence of TR
and T3 raised the question of how TR–RXR and the transcription
initiation machinery co-localize to the same sequence. In contrast
to most of the transcription initiation sites of promoters transcribed
by RNA polymerase II, the SVL cap site is required for basal
promoter activity (14), suggesting that this site may bind both a
transcription factor and the RNA polymerase II complex at the
same time. Interestingly, this sequence also corresponds to one of
the sites that bind the cellular transcriptional repressors which
Wiley et al. (15) purified from HeLa cell nuclear extracts. The
active fraction is mainly composed of three proteins, called
initiator binding proteins (IBPs), which bind with high affinity to
discrete sites, surrounding and located at the major transcription
initiation site of the SVL (see Fig. 8). The human estrogen-related
receptor (hERR1) is one major IBP component (15), while
testicular receptor 2 and testicular receptor 4, as well as
COUP-TFI and COUP-TFII, can interact with the sequence
centred at nt 380 (23,40) and for the two latter factors, to a lesser
extent to the binding site centred at nt 325 (41). In infected cells,
titration of these cellular factors may participate in the SV40 early
to late switch (15). Interestingly, all these factors are orphan
nuclear receptors and members of the steroid–thyroid hormone
receptor family. The importance of TR-mediated repression in
this context of multiple interactions still remains to be elucidated.
In summary, we have demonstrated that the major late
transcription initiation site of the SV40 genome, previously
characterized as a binding site for transcriptional repressors, is a
potent TRE. The presence of TR leads to strong repression of
 Nucleic Acids Research, 1997, Vol. 25, No. 91796
Figure 8. Compilation of the factors binding to the region surrounding the SVL promoter transcription initiation site. Light grey boxes, core promoter elements that
bind factors stimulating transcription as identified by Ayer and Dynan (14,42); GTFs, general transcription factors; DAP, downstream activator protein; dark grey boxes,
repressor binding sites interacting with IBPs. hERR1 has been identified as one of the IBPs, while COUP-TFI, COUP-TFII, TR2 and TR4 also bind to the indicated
sites (15,23,40,41) and repress transcription.
SVL promoter activity, but this repression can be relieved by
addition of T3. Both TR-mediated repression and derepression do
not affect the site of transcription initiation nor splicing of the VP1
intron. These results raise the question, not yet resolved, of how
does the transcription machinery overcome cluttering at the
initiation site. Finally, our results demonstrate that one should be
cautious when using SVL in expression vectors designed for the
study of hormone responsiveness.
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